<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03500159</url>
  </required_header>
  <id_info>
    <org_study_id>AQX-1125-205</org_study_id>
    <nct_id>NCT03500159</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of AQX-1125 in Subjects With Chronic Prostatitis/Chronic Pelvic Pain Syndrome</brief_title>
  <acronym>CP/CPPS</acronym>
  <official_title>A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Trial to Evaluate the Efficacy and Safety of AQX-1125 (200 mg) in Male Subjects With Chronic Prostatitis/Chronic Pelvic Pain Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aquinox Pharmaceuticals (Canada) Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aquinox Pharmaceuticals (Canada) Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, multi-center, double-blind, parallel-group study, enrolling
      approximately 100 male subjects diagnosed with CP/CPPS to evaluate the effect of 12-week
      treatment with AQX-1125 (active drug) compared to placebo.

      The subjects will be randomized to receive orally once-daily either AQX-1125 (200 mg) or
      placebo in a 1:1 ratio across approximately 30 centers in North America (United States and
      Canada). The study will consist of a screening period of up to 3 weeks, a 12-week treatment
      period followed by a 4-week off drug safety follow-up period, and an ophthalmic safety
      follow-up call at 3 months and visit at 6 months post last dose, for a total study duration
      of about 41 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor's Decision
  </why_stopped>
  <start_date type="Actual">April 18, 2018</start_date>
  <completion_date type="Actual">July 17, 2018</completion_date>
  <primary_completion_date type="Actual">July 17, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Week 12 in Maximum Daily Pelvic Pain (Mean)</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Change from Baseline to Week 12 for AQX-1125 200 mg compared to placebo in the maximum daily pelvic pain score based on a standardized 11-point numeric rating scale (NRS) recorded by electronic diary (eDiary)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in NIH-CPSI</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Change from Baseline to Week 12 for AQX-1125 200 mg compared to placebo in NIH Chronic Prostatitis Symptom Index (NIH-CPSI) pain subscale and all domains total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in IIEF-EF</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Change from Baseline to Week 12 for AQX-1125 200 mg compared to placebo in Male sexual health as measured using the International Index of Erectile Function Questionnaire, Erectile Function Domain (IIEF-EF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in Average Daily Pelvic Pain (eDiary),</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Change from Baseline to Week 12 for AQX-1125 200 mg compared to placebo in the average daily pelvic pain score based on a standardized 11-point numeric rating scale (NRS) recorded by electronic diary (eDiary)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in Average and Maximum Pelvic Pain Scores in Clinic</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Change from Baseline to Week 12 for AQX-1125 200 mg compared to placebo in the average and maximum pelvic pain score based on a standardized 11-point numeric rating scale (NRS) recorded on paper-based questionnaire at clinic visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in 24-hour Voiding Frequency (eDiary)</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Change from Baseline to Week 12 for AQX-1125 200 mg compared to placebo in voiding frequency as recorded by electronic diary (eDiary)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time Course of Effects From Baseline Through to Week 16: AQX-1125 200 mg Compared to Placebo for Each of the Pain and Symptom Scale Endpoints</measure>
    <time_frame>16 Weeks</time_frame>
    <description>Change from Baseline at each clinic visit for AQX-1125 200 mg compared to placebo for; Mean of maximum daily pelvic pain score (eDiary), NIH-CPSI pain subscale and all domains total score, IIEF-EF, Mean of average daily pelvic pain scores (eDiary), average and maximum pelvic pain (Paper-based NRS in clinic), and 24-hour voiding frequency (eDiary)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to Treatment Compared to Placebo at Week 12 as Measured by the GRA</measure>
    <time_frame>12 Weeks</time_frame>
    <description>AQX-1125 200 mg compared to placebo as measured by the Global Response Assessment (GRA) at Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to Treatment Compared to Placebo at Week 12 as Measured by the PGI-C</measure>
    <time_frame>12 Weeks</time_frame>
    <description>AQX-1125 200 mg compared to placebo as measured by the Patient's Global Impression of Change Scale (PGI-C) at Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to Treatment Compared to Placebo at Week 12 as Measured by the PGI-S</measure>
    <time_frame>12 Weeks</time_frame>
    <description>AQX-1125 200 mg compared to placebo as measured by the Patient's Global Impression of Severity Scale (PGI-S) at Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Proportion of Subjects With ≥30% and ≥50% Improvement in Maximum Daily Pelvic Pain Compared to Placebo</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Comparison between AQX-1125 200 mg and placebo in proportion of subjects with ≥30% and ≥50% improvement in maximum daily pelvic pain (mean) based on a standardized 11-point numeric rating scale (NRS) recorded by eDiary at Week 6 and 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Proportion of Subjects With ≥30% and ≥50% Improvement in NIH-CPSI Pain Subscale Compared to Placebo</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Comparison between AQX-1125 200 mg and placebo in proportion of subjects with ≥30% and ≥50% improvement NIH-CPSI subscale at Week 6 and 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response to Treatment</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Response to treatment as defined by a decrease in maximum daily pelvic pain (eDiary) at Week 12 with a decrease or no change to concomitant analgesic medication use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuation of Study Medication Due to Treatment Failure</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and Severity of Adverse Events (AEs)</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Chronic Prostatitis</condition>
  <condition>Chronic Pelvic Pain Syndrome</condition>
  <arm_group>
    <arm_group_label>AQX-1125</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AQX-1125 200 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AQX-1125 200 mg</intervention_name>
    <description>Synthetic SHIP1 activator</description>
    <arm_group_label>AQX-1125</arm_group_label>
    <other_name>Rosiptor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Appearance and weight matched tablets without the active product ingredient</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provide written informed consent and the willingness and ability to comply with all
             aspects of the study requirements

          -  Males, ≥18 and ≤80 years of age at Screening Visit 1

          -  Have pain or discomfort in the pelvic region for at least 3 months in the last 6
             months, in the absence of a urinary tract infection or other pelvic/urological cause,
             and have a physician diagnosis of CP/CPPS (NIH Prostatitis Category III)

          -  Subjects must agree to use a condom for sexual intercourse from Screening Visit 1
             until at least 90 days after the last dose of study drug, unless they have been
             surgically sterilized (vasectomy) for a minimum of 6 months

          -  Must be capable of voiding independently for 30 days prior to screening

        Exclusion Criteria:

          -  Diagnosis of NIH Prostatitis Categories I (acute prostatitis) or II (chronic
             bacterial) prostatitis

          -  Diagnosis of interstitial cystitis/bladder pain syndrome (IC/BPS) with symptoms of
             pain, pressure, or discomfort perceived to be related to the bladder, and associated
             lower urinary symptoms for &gt;6 weeks in the absence of infection or other identifiable
             causes

          -  Relief of pelvic pain after voiding

          -  Post-void residual volume &gt;150 mL

          -  Have had an unresolved (positive bacterial urine culture) urinary tract infection
             within 8 weeks (inclusive) prior to Screening Visit 1

          -  History of previous prostate or bladder intervention within 1 month of Screening Visit
             1, history of microwave therapy, transurethral resection of the prostate,
             transurethral radiofrequency thermotherapy, transurethral incision of the prostate,
             transurethral needle ablation, transurethral laser vaporization of the prostate,
             Urolift®, Rezum, and other urological interventions within 6 months of Screening Visit
             1

          -  Unilateral testicular or scrotal pain as the sole symptom of CP/CPPS

          -  Ongoing, symptomatic urethral stricture disease

          -  Neurologic disease or disorder affecting the bladder, ability to void spontaneously,
             or directly contributing to urinary symptoms (e.g., multiple sclerosis, autonomic
             neuropathy)

          -  Severe, excruciating pain during rectal exam (i.e. an &quot;inability to perform the exam&quot;)

          -  History of chronic substance abuse, dependency or abuse of opiates, or other narcotics
             within the last 2 years

          -  Any prior history of pelvic cancer (e.g., colorectal, genitourinary) or treatment
             (radiation or chemotherapy) thereof

          -  Major surgery within 3 months prior to Screening Visit 1

          -  Have any other condition/disease which, in the opinion of the Investigator, could
             compromise subject safety or interfere with the subject's participation in the study
             or in the evaluation of the study results.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Shoskes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site 1026</name>
      <address>
        <city>Homewood</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 1010</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 1004</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 1028</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 1018</name>
      <address>
        <city>Los Alamitos</city>
        <state>California</state>
        <zip>90720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 1016</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 1020</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 1027</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 1013</name>
      <address>
        <city>Coeur d'Alene</city>
        <state>Idaho</state>
        <zip>83814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 1015</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62769</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 1023</name>
      <address>
        <city>Jeffersonville</city>
        <state>Indiana</state>
        <zip>47130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 1014</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 1012</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 1002</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 1011</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 1009</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 1021</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 1008</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 1019</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 1001</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 1017</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 1007</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 1022</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 1005</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6T 4S5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 1025</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 3J7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 1003</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6H 3P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 1024</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6A 3B5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>April 4, 2018</study_first_submitted>
  <study_first_submitted_qc>April 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2018</study_first_posted>
  <results_first_submitted>December 20, 2018</results_first_submitted>
  <results_first_submitted_qc>December 20, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 9, 2019</results_first_posted>
  <last_update_submitted>December 20, 2018</last_update_submitted>
  <last_update_submitted_qc>December 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatitis</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Pelvic Pain</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Somatoform Disorders</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 25, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT03500159/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 8, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/59/NCT03500159/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AQX-1125</title>
          <description>AQX-1125 200 mg
AQX-1125 200 mg: Synthetic SHIP1 activator</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Matching placebo
Placebo: Appearance and weight matched tablets without the active product ingredient</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study Terminated</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AQX-1125</title>
          <description>AQX-1125 200 mg
AQX-1125 200 mg: Synthetic SHIP1 activator</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Matching placebo
Placebo: Appearance and weight matched tablets without the active product ingredient</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.5" spread="6.36"/>
                    <measurement group_id="B2" value="50.0" spread="0.00"/>
                    <measurement group_id="B3" value="53.66" spread="5.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 12 in Maximum Daily Pelvic Pain (Mean)</title>
        <description>Change from Baseline to Week 12 for AQX-1125 200 mg compared to placebo in the maximum daily pelvic pain score based on a standardized 11-point numeric rating scale (NRS) recorded by electronic diary (eDiary)</description>
        <time_frame>12 Weeks</time_frame>
        <population>Study was terminated prematurely, no analysis was performed</population>
        <group_list>
          <group group_id="O1">
            <title>AQX-1125</title>
            <description>AQX-1125 200 mg
AQX-1125 200 mg: Synthetic SHIP1 activator</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Matching placebo
Placebo: Appearance and weight matched tablets without the active product ingredient</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Maximum Daily Pelvic Pain (Mean)</title>
          <description>Change from Baseline to Week 12 for AQX-1125 200 mg compared to placebo in the maximum daily pelvic pain score based on a standardized 11-point numeric rating scale (NRS) recorded by electronic diary (eDiary)</description>
          <population>Study was terminated prematurely, no analysis was performed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in NIH-CPSI</title>
        <description>Change from Baseline to Week 12 for AQX-1125 200 mg compared to placebo in NIH Chronic Prostatitis Symptom Index (NIH-CPSI) pain subscale and all domains total score</description>
        <time_frame>12 Weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in IIEF-EF</title>
        <description>Change from Baseline to Week 12 for AQX-1125 200 mg compared to placebo in Male sexual health as measured using the International Index of Erectile Function Questionnaire, Erectile Function Domain (IIEF-EF)</description>
        <time_frame>12 Weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in Average Daily Pelvic Pain (eDiary),</title>
        <description>Change from Baseline to Week 12 for AQX-1125 200 mg compared to placebo in the average daily pelvic pain score based on a standardized 11-point numeric rating scale (NRS) recorded by electronic diary (eDiary)</description>
        <time_frame>12 Weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in Average and Maximum Pelvic Pain Scores in Clinic</title>
        <description>Change from Baseline to Week 12 for AQX-1125 200 mg compared to placebo in the average and maximum pelvic pain score based on a standardized 11-point numeric rating scale (NRS) recorded on paper-based questionnaire at clinic visits.</description>
        <time_frame>12 Weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in 24-hour Voiding Frequency (eDiary)</title>
        <description>Change from Baseline to Week 12 for AQX-1125 200 mg compared to placebo in voiding frequency as recorded by electronic diary (eDiary)</description>
        <time_frame>12 Weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Course of Effects From Baseline Through to Week 16: AQX-1125 200 mg Compared to Placebo for Each of the Pain and Symptom Scale Endpoints</title>
        <description>Change from Baseline at each clinic visit for AQX-1125 200 mg compared to placebo for; Mean of maximum daily pelvic pain score (eDiary), NIH-CPSI pain subscale and all domains total score, IIEF-EF, Mean of average daily pelvic pain scores (eDiary), average and maximum pelvic pain (Paper-based NRS in clinic), and 24-hour voiding frequency (eDiary)</description>
        <time_frame>16 Weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response to Treatment Compared to Placebo at Week 12 as Measured by the GRA</title>
        <description>AQX-1125 200 mg compared to placebo as measured by the Global Response Assessment (GRA) at Week 12</description>
        <time_frame>12 Weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response to Treatment Compared to Placebo at Week 12 as Measured by the PGI-C</title>
        <description>AQX-1125 200 mg compared to placebo as measured by the Patient's Global Impression of Change Scale (PGI-C) at Week 12</description>
        <time_frame>12 Weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response to Treatment Compared to Placebo at Week 12 as Measured by the PGI-S</title>
        <description>AQX-1125 200 mg compared to placebo as measured by the Patient's Global Impression of Severity Scale (PGI-S) at Week 12</description>
        <time_frame>12 Weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Proportion of Subjects With ≥30% and ≥50% Improvement in Maximum Daily Pelvic Pain Compared to Placebo</title>
        <description>Comparison between AQX-1125 200 mg and placebo in proportion of subjects with ≥30% and ≥50% improvement in maximum daily pelvic pain (mean) based on a standardized 11-point numeric rating scale (NRS) recorded by eDiary at Week 6 and 12</description>
        <time_frame>12 Weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Proportion of Subjects With ≥30% and ≥50% Improvement in NIH-CPSI Pain Subscale Compared to Placebo</title>
        <description>Comparison between AQX-1125 200 mg and placebo in proportion of subjects with ≥30% and ≥50% improvement NIH-CPSI subscale at Week 6 and 12</description>
        <time_frame>12 Weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response to Treatment</title>
        <description>Response to treatment as defined by a decrease in maximum daily pelvic pain (eDiary) at Week 12 with a decrease or no change to concomitant analgesic medication use.</description>
        <time_frame>12 Weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Discontinuation of Study Medication Due to Treatment Failure</title>
        <time_frame>12 Weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency and Severity of Adverse Events (AEs)</title>
        <time_frame>12 Weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>16 Weeks (12 weeks treatment period and 4 week post last dose follow up)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>AQX-1125</title>
          <description>AQX-1125 200 mg
AQX-1125 200 mg: Synthetic SHIP1 activator</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Matching placebo
Placebo: Appearance and weight matched tablets without the active product ingredient</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Restrictions are specific to applicable clinical trial agreements with PI(s)</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical</name_or_title>
      <organization>Aquinox Pharmaceuticals (Canada) Inc.</organization>
      <phone>604-629-9223</phone>
      <email>clinical@aqxpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

